Back to top
more

ATI Physical Therapy (ATIP)

(Real Time Quote from BATS)

$6.07 USD

6.07
7,781

+0.17 (2.88%)

Updated Oct 17, 2024 02:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (15 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain CONMED Stock in Your Portfolio

by Zacks Equity Research

CNMD is poised for growth with strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.

Here's Why You Should Retain AMN HealthCare Stock in Your Portfolio

by Zacks Equity Research

AMN shows growth potential with its broad services and high demand but faces challenges from industry regulations and strong competition in the staffing space.

Inogen Stock Rises 47% in 6 Months: What's Driving the Rally?

by Zacks Equity Research

INGN shows impressive momentum, driven by strong sales growth, an expanding product portfolio and significant advancements in portable oxygen technology.

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?

by Zacks Equity Research

GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.

Here's Why You Should Add AngioDynamics Stock to Your Portfolio

by Zacks Equity Research

ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

by Zacks Equity Research

OPK's growth is fueled by Rayaldee's success and strategic partnerships. However, stiff competition and overdependence on its lead product are concerns.

Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System

by Zacks Equity Research

AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.

GE HealthCare Stock Likely to Rise After FDA Approval of Flyrcado

by Zacks Equity Research

GEHC's Flyrcado, a first-of-its-kind PET tracer for coronary artery disease, receives FDA approval, expanding diagnostic access and improving patient outcomes.

Axonics Shares Fall Despite Australia's Approval for R20 SNM Device

by Zacks Equity Research

AXNX's R20 rechargeable SNM system, offering long-lasting treatment for bladder and bowel dysfunction, gains approval in Australia.

MultiPlan Stock Falls Even After NRHA Rural Healthcare Deal

by Zacks Equity Research

MPLN and NRHA team up to empower rural healthcare providers with innovative technology and data-driven solutions, improving access, quality and affordability.

Tactile Medical Stock Rises After Positive Flexitouch Trial Results

by Zacks Equity Research

TCMD announces a new study evaluating Flexitouch. The study reveals significant improvements in health-related quality of life and clinical outcomes.

ICU Medical's Stock Rises Despite Bivona Tracheostomy Tube Recall

by Zacks Equity Research

ICUI's Smiths Medical recalls Bivona tracheostomy tubes over a defect that may lead to serious health risks, including airway loss and death.

Trinity Biotech's Stock Rises After Acquisition of Metabolomics

by Zacks Equity Research

TRIB acquires Metabolomics Diagnostics, expanding its platform with cutting-edge tech to enhance diagnostics in maternal health and diabetes management.

Cardinal Health Stock Likely to Gain From the Acquisition of ION

by Zacks Equity Research

CAH is set to acquire Oncology Network for $1.115 billion, expanding its oncology offerings while supporting community-based cancer care across 10 states.

ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe

by Zacks Equity Research

AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.

Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

by Zacks Equity Research

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

GE HealthCare Shares Rise After AI-Powered Venue Sprint's Launch

by Zacks Equity Research

GEHC introduces Venue Sprint, a portable AI-enabled ultrasound device offering wireless probes, real-time insights and advanced clinical tools for improved care.

BD Stock Rises as Neopak XtraFlow Syringe Expands in Biologics

by Zacks Equity Research

BDX launches the Neopak XtraFlow Glass Prefillable Syringe, enhancing drug delivery for biologics and expanding capacity with new high-volume production lines.

Merit Medical Stock Falls Despite Positive WRAPSODY Trial Results

by Zacks Equity Research

MMSI announces 6-month results from its WRAPSODY WAVE trial, showing superior efficacy in extending AV fistula patency for dialysis patients.

ATI Physical Therapy (ATIP) Upgraded to Buy: Here's Why

by Zacks Equity Research

ATI Physical Therapy (ATIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bears are Losing Control Over ATI Physical Therapy (ATIP), Here's Why It's a 'Buy' Now

by Zacks Equity Research

ATI Physical Therapy (ATIP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

ATI Physical Therapy, Inc. (ATIP) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

ATI Physical Therapy (ATIP) delivered earnings and revenue surprises of 7.60% and 0.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Chemed (CHE) Q1 Earnings Miss Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of -4.94% and 0.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ATI Physical Therapy, Inc. (ATIP) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ATI Physical Therapy, Inc. (ATIP) delivered earnings and revenue surprises of -351.43% and 1.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Tops Q2 Earnings Estimates

by Zacks Equity Research

Amedisys (AMED) delivered earnings and revenue surprises of 28.04% and 2.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?